MA45655A - Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation - Google Patents

Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation

Info

Publication number
MA45655A
MA45655A MA045655A MA45655A MA45655A MA 45655 A MA45655 A MA 45655A MA 045655 A MA045655 A MA 045655A MA 45655 A MA45655 A MA 45655A MA 45655 A MA45655 A MA 45655A
Authority
MA
Morocco
Prior art keywords
tau protein
hyperphosphorylated tau
specific antibodies
use methods
protein
Prior art date
Application number
MA045655A
Other languages
English (en)
Other versions
MA45655B1 (fr
Inventor
Ayodeji Abdur-Rasheed Asuni
Søren Christensen
Justus Claus Alfred Daechsel
Laurent David
Lone Helbo
Thomas Jensen
Karsten Juhl
Kristian Kjaergaard
Mauro Marigo
Jan Torleif Pedersen
Lars Østergaard Pedersen
Nina Helen Rosenqvist
Lena Tagmose
Christiane Volbracht
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA45655A publication Critical patent/MA45655A/fr
Publication of MA45655B1 publication Critical patent/MA45655B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)

Abstract

La présente invention concerne une classe d'anticorps monoclonaux se liant spécifiquement au résidu sérine phosphorylé en position 396 de la protéine tau hyperphosphorylée pathologique (phf) (ps396) avec une plus grande affinité. L'invention concerne également des procédés d'utilisation de ces molécules et des fragments de liaison à la protéine tau correspondants dans le cadre du traitement de la maladie d'alzheimer et d'autres tauopathies.
MA45655A 2016-07-12 2017-07-07 Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation MA45655B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201600416 2016-07-12
DKPA201700008 2017-01-04
DKPA201700005 2017-01-04
DKPA201700179 2017-03-14
PCT/EP2017/067067 WO2018011073A1 (fr) 2016-07-12 2017-07-07 Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA45655A true MA45655A (fr) 2019-05-22
MA45655B1 MA45655B1 (fr) 2021-04-30

Family

ID=60941665

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056165A MA56165A (fr) 2016-07-12 2017-07-07 Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA45655A MA45655B1 (fr) 2016-07-12 2017-07-07 Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA056165A MA56165A (fr) 2016-07-12 2017-07-07 Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation

Country Status (41)

Country Link
US (6) US10472415B2 (fr)
EP (2) EP3484916B1 (fr)
JP (2) JP7029415B2 (fr)
KR (1) KR102551971B1 (fr)
CN (2) CN109618556B (fr)
AU (2) AU2017295608B2 (fr)
BR (1) BR112018004916A2 (fr)
CA (1) CA3027561A1 (fr)
CL (1) CL2019000082A1 (fr)
CO (1) CO2018014325A2 (fr)
CY (1) CY1123995T1 (fr)
DK (1) DK3484916T3 (fr)
DO (1) DOP2018000281A (fr)
EC (1) ECSP19005417A (fr)
ES (1) ES2862427T3 (fr)
GE (1) GEP20217222B (fr)
HR (1) HRP20210522T1 (fr)
HU (1) HUE053679T2 (fr)
IL (1) IL263530B2 (fr)
JO (1) JOP20180117B1 (fr)
LT (1) LT3484916T (fr)
MA (2) MA56165A (fr)
MX (1) MX2019000476A (fr)
MY (1) MY197836A (fr)
NI (1) NI201900003A (fr)
NZ (1) NZ748983A (fr)
PE (1) PE20190227A1 (fr)
PH (1) PH12018502613B1 (fr)
PL (1) PL3484916T3 (fr)
PT (1) PT3484916T (fr)
RS (1) RS61646B1 (fr)
RU (1) RU2760875C1 (fr)
SG (1) SG11201811015RA (fr)
SI (1) SI3484916T1 (fr)
SM (1) SMT202100194T1 (fr)
SV (1) SV2019005807A (fr)
TN (1) TN2018000419A1 (fr)
TW (1) TWI747922B (fr)
UA (1) UA124104C2 (fr)
WO (1) WO2018011073A1 (fr)
ZA (1) ZA201808329B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014097474A1 (fr) 2012-12-21 2014-06-26 独立行政法人放射線医学総合研究所 Nouveau composé pour imager la protéine tau accumulée dans le cerveau
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
NZ748983A (en) 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
CA3045294A1 (fr) 2016-12-07 2018-06-14 Genentech, Inc. Anticorps anti-tau et methodes d'utilisation
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
JP7217710B2 (ja) * 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
UA129617C2 (uk) 2017-10-16 2025-06-18 Еісаі Р Енд Д Менеджмент Ко., Лтд. Антитіло до тау та його застосування
JP2021512602A (ja) * 2018-02-01 2021-05-20 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウに特異的に結合する結合分子
AU2019232631A1 (en) 2018-03-05 2020-09-24 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
JP7293343B2 (ja) 2018-05-09 2023-06-19 アプリノイア セラピューティクス リミテッド ヘテロアリール化合物及びその使用
EP3870292A4 (fr) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
US12365724B2 (en) 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
JP2022527087A (ja) 2019-03-28 2022-05-30 ハー・ルンドベック・アクチエゼルスカベット タウオパチーを診断するためのｐＳ３９６アッセイの使用
JP7181438B2 (ja) * 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
WO2021097243A1 (fr) 2019-11-13 2021-05-20 Aprinoia Therapeutics Inc. Composés pour dégrader des agrégats de protéine tau et leurs utilisations
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
CA3227440A1 (fr) 2021-07-27 2023-02-02 Stand Therapeutics Co., Ltd. Marqueur peptidique et acide nucleique codant pour celui-ci
CA3228786A1 (fr) * 2021-08-25 2023-03-02 Ibio, Inc. Anticorps anti-cd25
WO2025090815A1 (fr) * 2023-10-24 2025-05-01 Janssen Pharmaceuticals, Inc. Méthode de traitement de la maladie d'alzheimer preclinique

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
ATE386115T1 (de) 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
EP0746609A4 (fr) 1991-12-17 1997-12-17 Genpharm Int Animaux transgeniques non humains capables de produire des anticorps heterologues
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1940442A4 (fr) 2005-08-04 2009-08-19 Einstein Coll Med Phosphorylation de tau par abl
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
WO2009033743A1 (fr) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations
WO2010144711A2 (fr) 2009-06-10 2010-12-16 New York University Ciblage immunologique de protéines tau pathologiques
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2625198B1 (fr) * 2010-10-07 2015-07-22 AC Immune S.A. Anticorps dirigés contre tau phosphorylée
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
US9506051B2 (en) * 2011-05-20 2016-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
CN108034005B (zh) * 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
EP2834270B1 (fr) 2012-04-05 2019-10-30 AC Immune S.A. Anticorps tau humanisé
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
CA2902026C (fr) 2013-03-13 2023-08-29 Prothena Biosciences Limited Immunotherapie contre tau
WO2014170549A1 (fr) 2013-04-16 2014-10-23 Glykos Finland Oy Procédé pour la génération de cellules souches pluripotentes induites
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
KR101838832B1 (ko) 2014-01-23 2018-03-14 아사히 가세이 가부시키가이샤 블록 공중합체 조성물 및 점접착제 조성물
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
NZ748983A (en) 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7217710B2 (ja) 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Also Published As

Publication number Publication date
US20220177557A1 (en) 2022-06-09
CN116041504A (zh) 2023-05-02
ES2862427T3 (es) 2021-10-07
PE20190227A1 (es) 2019-02-13
KR20190028436A (ko) 2019-03-18
IL263530B2 (en) 2023-02-01
SI3484916T1 (sl) 2021-08-31
WO2018011073A1 (fr) 2018-01-18
SG11201811015RA (en) 2019-01-30
JP2022023096A (ja) 2022-02-07
JP7029415B2 (ja) 2022-03-03
US20190284266A1 (en) 2019-09-19
DK3484916T3 (da) 2021-04-06
US10472415B2 (en) 2019-11-12
ECSP19005417A (es) 2019-01-31
BR112018004916A2 (en) 2018-12-11
DOP2018000281A (es) 2019-02-15
KR102551971B1 (ko) 2023-07-07
EP3878864A1 (fr) 2021-09-15
SMT202100194T1 (it) 2021-05-07
CL2019000082A1 (es) 2019-04-05
US20190284265A1 (en) 2019-09-19
SV2019005807A (es) 2019-02-13
EP3484916B1 (fr) 2021-03-03
HUE053679T2 (hu) 2021-07-28
PL3484916T3 (pl) 2021-07-19
CN109618556A (zh) 2019-04-12
TW201809004A (zh) 2018-03-16
NZ748983A (en) 2022-12-23
JOP20180117A1 (ar) 2019-01-30
TWI747922B (zh) 2021-12-01
UA124104C2 (uk) 2021-07-21
HRP20210522T1 (hr) 2021-05-14
RS61646B1 (sr) 2021-04-29
US20250257124A1 (en) 2025-08-14
CY1123995T1 (el) 2022-05-27
AU2017295608B2 (en) 2024-01-04
RU2760875C1 (ru) 2021-12-01
MA45655B1 (fr) 2021-04-30
MX2019000476A (es) 2019-06-10
MA56165A (fr) 2022-04-20
US20180016330A1 (en) 2018-01-18
NI201900003A (es) 2020-04-27
ZA201808329B (en) 2020-02-26
PH12018502613B1 (en) 2023-02-01
PT3484916T (pt) 2021-03-31
IL263530A (en) 2019-01-31
US10647762B2 (en) 2020-05-12
AU2017295608A1 (en) 2018-12-20
CA3027561A1 (fr) 2018-01-18
US20200109192A1 (en) 2020-04-09
LT3484916T (lt) 2021-04-26
JP7244600B2 (ja) 2023-03-22
TN2018000419A1 (en) 2020-06-15
US10487142B2 (en) 2019-11-26
IL263530B (en) 2022-10-01
US12129289B2 (en) 2024-10-29
CO2018014325A2 (es) 2019-01-18
EP3484916A1 (fr) 2019-05-22
US11111290B2 (en) 2021-09-07
JP2019529336A (ja) 2019-10-17
JOP20180117B1 (ar) 2022-03-14
PH12018502613A1 (en) 2019-09-30
MY197836A (en) 2023-07-20
AU2024201450A1 (en) 2024-03-28
GEP20217222B (en) 2021-02-10
CN109618556B (zh) 2022-10-21

Similar Documents

Publication Publication Date Title
MA45655A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
NO20082288L (no) Monoklonalt anti-ADDL-antistoff og anvendelse derav
MA33339B1 (fr) Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
MA29409B1 (fr) Anticorps diriges contre le peptide amyloïde -beta, et methodes pour leurs utilisations
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
MA40224B1 (fr) Anticorps se liant aux protofibrilles ass améliorés
EA201992688A1 (ru) Средства, пути применения и способы лечения
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP1896588A4 (fr) NOUVELLE PROTÉINE DE LIAISON Aß, SES DÉRIVÉS PEPTIDIQUES ET LEURS UTILISATIONS
EA201892570A1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
MA35580B1 (fr) Composition pharmaceutique
CY1115021T1 (el) Μονοκλωνικα αντισωματα εναντι αμυλοειδους βητα πρωτεϊνης και χρησεις αυτων
MA38561A1 (fr) Anticorps anti-igf-1r à liaison fcrn abolie et leur utilisation dans le traitement de maladies vasculaires oculaires